用于选择性向整合素α4β1+ T系癌症的DNA阿普塔默-聚合物结合物
Ian I Cardle1,2, Jai Raman1, Dinh Chuong Nguyen3
1Department of Bioengineering, University of Washington, Seattle, Washington 98195, United States.
ACS applied materials & interfaces
|January 9, 2025
概括
研究人员发现了一种DNA吸收体HR7A1,它在T细胞癌症上向整合素α4β1 (VLA-4). 这种体显示出开发抗白血病和淋巴瘤新疗法的潜力,克服化疗抵抗.
科学领域:
- 生物技术是生物技术.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 针对T细胞恶性瘤是具有挑战性的,因为T细胞谱系重叠.
- 目前的化疗缺乏特异性,导致复发/耐药性疾病.
- 开发针对T细胞白血病和淋巴瘤的向疗法是一个至关重要的未满足的需求.
研究的目的:
- 发现和描述一种针对T细胞恶性瘤中的癌细胞的新型DNA吸收体.
- 为了研究aptamerHR7A1.1.的结合性质和治疗潜力.
- 为应对基于aptamer的疗法在体内翻译的挑战.
主要方法:
- 发现了具有对整合素α4β1 (VLA-4) 高 afinity 的 DNA aptamer HR7A1 .
- 切断阿巴和评估结合特异性的T系癌细胞与健康的免疫细胞.
- 低温电子显微镜 (cryo-EM) 和竞争研究以确定结合地点.
- 在体内障碍物的表征和聚合物-聚合物合物的合成.
主要成果:
- HR7A1 胺体对整合素α4β1 (VLA-4) 具有较低的纳米分子亲和力.
- 截断的阿帕特马显示选择性结合T系癌细胞.
- HR7A1与α4β1上的纤维素和VCAM-1结合到一个重叠的部位,这表明它有可能使癌症对化疗敏感.
- 阿普塔默-聚合物结合物是为了克服血清不稳定性和短半衰期等障碍而开发的.
结论:
- DNA 体HR7A1是向T细胞恶性瘤的有希望的候选者.
- HR7A1的结合机制有可能使血液癌症对化疗敏感.
- 开发的阿巴 - 聚合物合物代表了基于阿巴的活体治疗的可行策略.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.7K
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
7.6K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:25Selectins
3.2K
Cell adhesion is an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.2K
01:10Integrins
3.8K
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
3.8K